{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T10:22:22Z","timestamp":1751106142165,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cervical cancer is the fourth most common cancer in women worldwide. A successful screening concept for cervical cancer reduces the incidence and mortality of cervical cancer. Quality indicators (QIs) derived from the screening guidelines for cervical cancer and used by the certified dysplasia units and dysplasia consultancies are evaluated in this paper. The aim of this paper is to present the current data from the annual reports of these units and consultancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The results of the basic data and indicators for the audit year 2022 in the gynaecological dysplasia consultancies and units are presented. In 2022, 84 dysplasia consultancies and 42 units were audited. 40 units and 84 consultancies are included in the annual report. QI outcomes for patients treated in certified dysplasia units and dysplasia consultancies are analysed. Median, overall proportion, and standard deviation were calculated for each QI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The indicator year 2021 was analysed, which was audited in 2022 and evaluated in 2023. A total of nine QIs were analysed. Most target goals were met by the 84 certified dysplasia consultancies and by the 40 dysplasia units. The QIs evaluated are implemented to a very high degree. The targets for the three QIs were achieved by both the dysplasia consultancies and the units in at least 95% of the certified centres (QI 1: 100%, QI 2: 95%, QI 3: 100%; QI 1: 100%, QI 2: 97%, QI 3: 100%, respectively). The presentation of patients to the tumour board by the consultancies\/units is working; the units are attending the tumour board more regularly than in previous years. Where the target was not met, the auditors issued deviations or reduced the duration of the certificate. The cases are discussed intensively in the sense of an individual case analysis and with the determination of measures on-site.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The targets for the various indicators were largely met by the dysplasia consultancies and units in the 2022 audit year. The certification of gynaecological dysplasia consultancies\/units which have to cooperate with certified gynaecological cancer centres, has for the first time ensured the continuity of healthcare from prevention and early diagnosis to treatment of gynaecological cancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-024-07694-w","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:02:37Z","timestamp":1724911357000},"page":"2191-2202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality assurance using quality indicators for prevention and early detection of cervical cancer in certified gynaecological dysplasia units and consultancies"],"prefix":"10.1007","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3808-3385","authenticated-orcid":false,"given":"Lena","family":"Steinkasserer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Wesselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dannecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hachenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Jentschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"1","key":"7694_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sxmr.2019.09.005","volume":"8","author":"SL Bedell","year":"2020","unstructured":"Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT (2020) Cervical cancer screening: past, present, and future. Sex Med Rev 8(1):28\u201337","journal-title":"Sex Med Rev"},{"unstructured":"Koch-Institut R (2019) Geb\u00e4rmutterhalskrebs (Zervixkarzinom), updated 30.09.2022. Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Gebaermutterhalskrebs\/gebaermutterhalskrebs_node.html.Accessed 04 Aug 2024","key":"7694_CR2"},{"issue":"7","key":"7694_CR3","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/diagnostics12071748","volume":"12","author":"FA Stuebs","year":"2022","unstructured":"Stuebs FA, Koch MC, Dietl AK, Adler W, Geppert C, Hartmann A et al (2022) Cytology and high-risk human papillomavirus test for cervical cancer screening assessment. Diagnostics (Basel) 12(7):1748","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"7694_CR4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s00103-018-2835-7","volume":"61","author":"J Bujan Rivera","year":"2018","unstructured":"Bujan Rivera J, Klug SJ (2018) Cervical cancer screening in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61(12):1528\u20131535","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"2","key":"7694_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/a-1671-2158","volume":"82","author":"MW Beckmann","year":"2022","unstructured":"Beckmann MW, Stubs FA, Koch MC, Mallmann P, Dannecker C, Dietl A et al (2022) Diagnosis, Therapy and follow-up of cervical cancer guideline of the DGGG, DKG and DKH S3-Level, AWMF epidemiology screening diagnostics and therapy. Geburtshilfe Frauenheilkd 82(2):139\u2013180","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"7694_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/a-1671-2446","volume":"82","author":"T Fehm","year":"2022","unstructured":"Fehm T, Stubs FA, Koch MC, Mallmann P, Dannecker C, Dietl A et al (2022) Diagnosis, therapy and follow-up of cervical cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF registry no. 032\/033OL, May 2021)-part 2 with recommendations on psycho-oncology, rehabilitation, follow-up, recurrence, palliative therapy and healthcare facilities. Geburtshilfe Frauenheilkd 82(2):181\u2013205","journal-title":"Geburtshilfe Frauenheilkd"},{"unstructured":"Bundesausschuss G (2018) Richtlinie f\u00fcr organisierte Krebsfr\u00fcherkennungsprogramme und Krebsfr\u00fcherkennungs-Richtlinie: Programm zur Fr\u00fcherkennung von Zervixkarzinomen","key":"7694_CR7"},{"issue":"6","key":"7694_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.zefq.2015.09.007","volume":"109","author":"T Langer","year":"2015","unstructured":"Langer T, Follmann M (2015) The German guideline program in oncology (GGPO): a central core of an evidence-based, patient-centered interdisciplinary oncology? Z Evid Fortbild Qual Gesundhwes 109(6):437\u2013444","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"unstructured":"Thomas Langer SW, Christoph Kowalski (2017) Qualit\u00e4tsindikatoren in der Onkologie. Versorgungsforschung","key":"7694_CR9"},{"issue":"9","key":"7694_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1055\/s-0034-1383042","volume":"74","author":"MW Beckmann","year":"2014","unstructured":"Beckmann MW, Quaas J, Bischofberger A, Kammerle A, Lux MP, Wesselmann S (2014) Establishment of the certification system \u201cgynaecological dysplasia\u201d in Germany. Geburtshilfe Frauenheilkd 74(9):860\u2013867","journal-title":"Geburtshilfe Frauenheilkd"},{"unstructured":"Colposcopy EFF. The EFC Quality and Standards Group 2020. Available from: https:\/\/efcolposcopy.eu\/quality-and-standards-group\/. Accessed 04 Aug 2024","key":"7694_CR11"},{"unstructured":"Candice A, Tedeschi N (2013) The requirements in this booklet are effective for any mentee applying for the colposcopy mentorship program on or after March 21. Available from: https:\/\/www.asccp.org\/Assets\/7494717c-98c0-4d70-81cc-0aafebf017ed\/635947807358470000\/asccp-cmp-booklet-2013-pdf. Accessed 04 Aug 2024","key":"7694_CR12"},{"unstructured":"J. Quaas AB, M.P. Lux, S. Wesselmann, M.W. Beckmann (2015) Zertifizierungsprogramm f\u00fcr Gyn\u00e4kologische Dysplasie-Sprechstunden. DKG-aktuell. 1\u20134.","key":"7694_CR13"},{"unstructured":"e.V. DK, e.V. DGfGuG, e.V. AGO, e.V. AZuK, Krebszentren ZG (2023) Jahresbericht der zertifizierten Gyn\u00e4kologischen Dysplasie-Sprechstunden - Kennzahlenauswertung. Available from: https:\/\/www.krebsgesellschaft.de\/jahresberichte.html?file=files\/dkg\/deutsche-krebsgesellschaft\/content\/pdf\/Zertifizierung\/Jahresberichte%20mit%20DOI%20und%20ISBN\/qualitaetsindikatoren_gynaekologische-dysplasien_2023-A1_230526.pdf&cid=112679. Accessed 04 Aug 2024]","key":"7694_CR14"},{"unstructured":"e.V. DK, e.V. DGfGuG, e.V. AGO, e.V. AZuK, Krebszentren ZG (2023) Jahresbericht der zertifizierten Gyn\u00e4kologischen Dysplasie-Einheiten - Kennzahlenauswertung. Available from: https:\/\/www.krebsgesellschaft.de\/jahresberichte.html?file=files\/dkg\/deutsche-krebsgesellschaft\/content\/pdf\/Zertifizierung\/Jahresberichte%20mit%20DOI%20und%20ISBN\/qualitaetsindikatoren_gynaekologische-dysplasien_2023-A1_230526.pdf&cid=112679. Accessed 04 Aug 2024","key":"7694_CR15"},{"unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Pr\u00e4vention des Zervixkarzinoms, Langversion 1.1, 2020, AWMF Registernummer: 015\/027OL 2020 [Available from: http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/zervixkarzinom-praevention\/","key":"7694_CR16"},{"issue":"5","key":"7694_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00432-022-04060-8","volume":"149","author":"E Griesshammer","year":"2023","unstructured":"Griesshammer E, Wesselmann S, Beckmann MW, Dannecker C, Wagner U, Sibert NT et al (2023) Quality assurance and improvement in oncology using guideline-derived quality indicators - results of gynaecological cancer centres certified by the German cancer society (DKG). J Cancer Res Clin Oncol 149(5):1703\u20131715","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"7694_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/j.1471-0528.1999.tb08137.x","volume":"106","author":"EJ Junor","year":"1999","unstructured":"Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106(11):1130\u20131136","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"7694_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000517893","volume":"106","author":"J Ruckher","year":"2022","unstructured":"Ruckher J, Lobitz J, Follmann M, Derenz S, Schmidt S, Mensah J et al (2022) Guideline-based quality indicators for kidney and bladder cancer in Germany: development and implementation. Urol Int 106(4):360\u2013367","journal-title":"Urol Int"},{"key":"7694_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05769-4","author":"FA Stuebs","year":"2023","unstructured":"Stuebs FA, Beckmann MW, Fehm T, Dannecker C, Follmann M, Langer T et al (2023) Implementation and update of guideline-derived quality indicators for cervical cancer in gynecological cancer centers certified by the German cancer society (DKG). J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-024-05769-4","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07694-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07694-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07694-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:28:49Z","timestamp":1726129729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07694-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["7694"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07694-w","relation":{},"ISSN":["1432-0711"],"issn-type":[{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective analysis of dysplasia data from the German Cancer Society (DKG), which was ethically approved by the Ethics Committee of the German Cancer Society (DKG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}